These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15507217)

  • 1. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
    Truong JG; Newman AH; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
    Truong JG; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion increases striatal vesicular monoamine transport.
    Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
    Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
    Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J; Dougherty JJ; Nichols RA
    J Neurochem; 2006 Jul; 98(2):481-94. PubMed ID: 16805841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
    Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
    Truong JG; Rau KS; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
    Eyerman DJ; Yamamoto BK
    J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
    Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.
    Pickel VM; Chan J; Nirenberg MJ
    Synapse; 2002 Aug; 45(2):113-24. PubMed ID: 12112404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
    Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
    Staal RG; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content.
    Bemis JC; Seegal RF
    Toxicol Sci; 2004 Aug; 80(2):288-95. PubMed ID: 15115888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
    Ugarte YV; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2003 Jul; 472(3):165-71. PubMed ID: 12871750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats.
    Yoshida ST; Baella SA; Stuebner NM; Crawford CA; McDougall SA
    Brain Res; 2006 Feb; 1073-1074():269-75. PubMed ID: 16427034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.